Literature DB >> 21671084

Modifications of neuroactive steroid levels in an experimental model of nigrostriatal degeneration: potential relevance to the pathophysiology of Parkinson's disease.

Roberto Cosimo Melcangi1, Donatella Caruso, Giovanna Levandis, Federico Abbiati, Marie-Therese Armentero, Fabio Blandini.   

Abstract

An important link between neuroactive steroids and neurodegenerative disorders has recently been suggested. Indeed, in several neurodegenerative experimental models the levels of neuroactive steroids are affected and their administration exerts neuroprotective effects. However, scarce information has so far been obtained on the neuroactive steroid levels present in Parkinson's disease. To this aim, using an experimental model of loss of nigrostriatal dopaminergic neurons obtained by stereotaxic injection of the neurotoxin 6-hydroxydopamine (6-OHDA), we evaluated by liquid chromatography tandem mass spectrometry the levels of several neuroactive steroids in the striatum and cerebral cortex of 6-OHDA-lesioned male rats. Among the neuroactive steroid levels assessed (i.e., pregnenolone, progesterone, dihydroprogesterone, tetrahydroprogesterone, isopregnanolone, testosterone, dihydrotestosterone, 3α-diol, dehydroepiandrosterone, 17α-estradiol, and 17β-estradiol), we observed a significant decrease of pregnenolone in the striatum. A similar effect was also observed on the levels of dihydroprogesterone present in this cerebral area and also in the cerebral cortex. Interestingly, an increase of isopregnanolone also occurred in the striatum and in the cerebral cortex. Altogether, these results suggesting that progesterone metabolism is affected in an experimental model of Parkinson's disease further highlight the link between neuroactive steroids and the neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21671084     DOI: 10.1007/s12031-011-9570-y

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  40 in total

Review 1.  Neuroactive steroids: state of the art and new perspectives.

Authors:  R C Melcangi; L M Garcia-Segura; A G Mensah-Nyagan
Journal:  Cell Mol Life Sci       Date:  2008-03       Impact factor: 9.261

2.  Effects of female sex steroids on Parkinson's disease in postmenopausal women.

Authors:  E Strijks; J A Kremer; M W Horstink
Journal:  Clin Neuropharmacol       Date:  1999 Mar-Apr       Impact factor: 1.592

3.  Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: an exploratory case-control study.

Authors:  M D Benedetti; D M Maraganore; J H Bower; S K McDonnell; B J Peterson; J E Ahlskog; D J Schaid; W A Rocca
Journal:  Mov Disord       Date:  2001-09       Impact factor: 10.338

4.  Stereospecific prevention by 17beta-estradiol of MPTP-induced dopamine depletion in mice.

Authors:  S Callier; M Morissette; M Grandbois; T Di Paolo
Journal:  Synapse       Date:  2000-09-15       Impact factor: 2.562

5.  Molecular characterization of a first human 3(alpha-->beta)-hydroxysteroid epimerase.

Authors:  X F Huang; V Luu-The
Journal:  J Biol Chem       Date:  2000-09-22       Impact factor: 5.157

Review 6.  The 6-hydroxydopamine model: news from the past.

Authors:  Fabio Blandini; Marie-Therese Armentero; Emilia Martignoni
Journal:  Parkinsonism Relat Disord       Date:  2008-07-02       Impact factor: 4.891

Review 7.  Progesterone and progestins: neuroprotection and myelin repair.

Authors:  Michael Schumacher; Regine Sitruk-Ware; Alejandro F De Nicola
Journal:  Curr Opin Pharmacol       Date:  2008-11-06       Impact factor: 5.547

Review 8.  Estrogen and SERM neuroprotection in animal models of Parkinson's disease.

Authors:  Marc Morissette; Sara Al Sweidi; Sophie Callier; Thérèse Di Paolo
Journal:  Mol Cell Endocrinol       Date:  2008-04-22       Impact factor: 4.102

9.  Reduced progesterone metabolites protect rat hippocampal neurones from kainic acid excitotoxicity in vivo.

Authors:  I Ciriza; I Azcoitia; L M Garcia-Segura
Journal:  J Neuroendocrinol       Date:  2004-01       Impact factor: 3.627

10.  Pregnenolone sulfate induces NMDA receptor dependent release of dopamine from synaptic terminals in the striatum.

Authors:  Matthew T Whittaker; Terrell T Gibbs; David H Farb
Journal:  J Neurochem       Date:  2008-08-14       Impact factor: 5.372

View more
  9 in total

Review 1.  Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?

Authors:  Abdulmaged M Traish; Roberto Cosimo Melcangi; Marco Bortolato; Luis M Garcia-Segura; Michael Zitzmann
Journal:  Rev Endocr Metab Disord       Date:  2015-09       Impact factor: 6.514

Review 2.  New concepts in the study of the sexual differentiation and activation of reproductive behavior, a personal view.

Authors:  Jacques Balthazart
Journal:  Front Neuroendocrinol       Date:  2019-08-17       Impact factor: 8.606

Review 3.  Regulation of the Neurodegenerative Process Associated to Parkinson's Disease by CD4+ T-cells.

Authors:  Hugo González; Francisco Contreras; Rodrigo Pacheco
Journal:  J Neuroimmune Pharmacol       Date:  2015-05-28       Impact factor: 4.147

4.  Age-related changes in neuroactive steroid levels in 3xTg-AD mice.

Authors:  Donatella Caruso; Anna M Barron; Meghan A Brown; Federico Abbiati; Paloma Carrero; Christian J Pike; Luis M Garcia-Segura; Roberto C Melcangi
Journal:  Neurobiol Aging       Date:  2012-11-02       Impact factor: 4.673

5.  Peripheral vs. Central Sex Steroid Hormones in Experimental Parkinson's Disease.

Authors:  Simon McArthur; Glenda E Gillies
Journal:  Front Endocrinol (Lausanne)       Date:  2011-11-30       Impact factor: 5.555

6.  Neuroprotective changes in degeneration-related gene expression in the substantia nigra following acupuncture in an MPTP mouse model of Parkinsonism: Microarray analysis.

Authors:  Sujung Yeo; Keon Sang An; Yeon-Mi Hong; Yeong-Gon Choi; Bruce Rosen; Sung-Hoon Kim; Sabina Lim
Journal:  Genet Mol Biol       Date:  2014-03-17       Impact factor: 1.771

Review 7.  Progesterone in the Brain: Hormone, Neurosteroid and Neuroprotectant.

Authors:  Rachida Guennoun
Journal:  Int J Mol Sci       Date:  2020-07-24       Impact factor: 5.923

Review 8.  Androgens and Parkinson's Disease: A Review of Human Studies and Animal Models.

Authors:  Mélanie Bourque; Denis Soulet; Thérèse Di Paolo
Journal:  Androg Clin Res Ther       Date:  2021-12-23

9.  Clinical Effects of Piribedil in Adjuvant Treatment of Parkinson's Disease: A Meta-Analysis.

Authors:  Lu Peihua; Wang Jianqin
Journal:  Open Med (Wars)       Date:  2018-07-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.